Hyo-Soo Kim
From EverybodyWiki Bios & Wiki
| Hyo-Soo Kim | |
|---|---|
| Born | |
| 🎓 Alma mater | Seoul National University |
| 💼 Occupation | Physician, Medical scientist |
Hyo-Soo Kim (Korean: 김효수; born 1959) is a South Korean physician and medical scientist. He is a research professor at the Biomedical Research Institute of Seoul National University Hospital and a professor at the Seoul National University College of Medicine.[1] His research focuses on cardiovascular disease, particularly in the fields of stem cell therapy and gene therapy.
Education
- 1987–1994: PhD in Medicine, Seoul National University Graduate School
- 1985–1987: Master of Medicine, Seoul National University Graduate School
- 1978–1984: Doctor of Medicine (MD), Seoul National University College of Medicine
Career
- 2024–present: Research Professor, Biomedical Research Institute, Seoul National University Hospital
- 1994–present: Professor (previously Instructor, Assistant Professor, Associate Professor), College of Medicine, Seoul National University
- 2023–present: President, Asian Pacific Society of Cardiology (APSC)
- 2021–2022: Chairman, Board of Directors, Korean Society of Cardiology
- 2020–2023: Director, Biomedical Research Institute, Seoul National University Hospital
- 2016–2018: Chairman, Board of Directors, Korean Society of Lipid and Atherosclerosis
- 2016–2018: Chairman, Board of Directors, Korean Society of Interventional Cardiology
- 2009–present: Director, Center for Cell & Gene Therapy, Seoul National University Hospital
- 2012–2016: Director, Cardiovascular Center & Chief of Cardiology, Seoul National University Hospital
Awards
- 2016: Order of Service Merit (Republic of Korea Government)[2]
- 2014: Grand Prize, 24th Wunsch Medical Award (Korean Academy of Medical Sciences)[3]
- 2008: Grand Prize, 1st Asan Award in Medicine (Asan Foundation)[4]
Major Research
Kim has led clinical research on stem cell and gene therapies for cardiovascular diseases, as well as antiplatelet therapies. His work has been published in major international journals, including The Lancet, Cell Metabolism, and Cell Stem Cell.
Key publications:
- Kang J, Park KW, Han JK, Hwang D, Yang HM, Park S, … Kim HS. "Dual Antiplatelet Therapy After PCI According To Bleeding Risk: The HOST-BR Trial." Lancet (in press).
- Koo BK, Kang J, Park KW, … Kim HS. "Aspirin versus clopidrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM)." Lancet. 2021.[5]
- Kim HS, Kang J, Hwang D, … "Prasugrel-based de-escalation of dual antiplatelet therapy (HOST-REDUCE-POLYTECH-ACS)." Lancet. 2020.[6]
- Kang HJ, Kim HS, Zhang SY, … "Effects of intracoronary infusion of peripheral blood stem-cells… (MAGIC cell randomized clinical trial)." Lancet. 2004.[7]
- Lee S, Lee HC, Kwon YW, … Kim HS. "Adenylyl cyclase-associated protein 1 is a receptor for human resistin." Cell Metabolism. 2014.[8]
- Hur J, Choi JI, Lee H, … Kim HS. "CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells." Cell Stem Cell. 2016.[9]
This article "Hyo-Soo Kim" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Hyo-Soo Kim. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ https://www.snuh.org/board/B003/view.do?bbs_no=7177
- ↑ "[메디칼타임즈] 줄기세포 서울의대 김효수 교수 녹조근정훈장 수훈".
- ↑ "서울의대 김효수 교수 '제24회 분쉬의학상' 본상 수상". 20 November 2014.
- ↑ https://www.amc.seoul.kr/asan/depts/aam/K/content.do?menuId=3931
- ↑ Koo, B. K.; et al. (2021). "Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial". Lancet. 397 (10293): 2487–2496. doi:10.1016/S0140-6736(21)01063-1. PMID 34010616 Check
|pmid=value (help). - ↑ Kim, H. S.; Kang, J.; Hwang, D.; Han, J. K.; Yang, H. M.; Kang, H. J.; Koo, B. K.; Rhew, J. Y.; Chun, K. J.; Lim, Y. H.; Bong, J. M.; Bae, J. W.; Lee, B. K.; Park, K. W.; HOST-REDUCE-POLYTECH-ACS investigators (2020). "Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): An open-label, multicentre, non-inferiority randomised trial". Lancet. 396 (10257): 1079–1089. doi:10.1016/S0140-6736(20)31791-8. PMID 32882163 Check
|pmid=value (help). - ↑ Kang, H. J.; Kim, H. S.; Zhang, S. Y.; Park, K. W.; Cho, H. J.; Koo, B. K.; Kim, Y. J.; Soo Lee, D.; Sohn, D. W.; Han, K. S.; Oh, B. H.; Lee, M. M.; Park, Y. B. (2004). "Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial". Lancet. 363 (9411): 751–756. doi:10.1016/S0140-6736(04)15689-4. PMID 15016484.
- ↑ Lee, S.; Lee, H. C.; Kwon, Y. W.; Lee, S. E.; Cho, Y.; Kim, J.; Lee, S.; Kim, J. Y.; Lee, J.; Yang, H. M.; Mook-Jung, I.; Nam, K. Y.; Chung, J.; Lazar, M. A.; Kim, H. S. (2014). "Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes". Cell Metabolism. 19 (3): 484–497. doi:10.1016/j.cmet.2014.01.013. PMC 3969988. PMID 24606903.
- ↑ Hur, J.; Choi, J. I.; Lee, H.; Nham, P.; Kim, T. W.; Chae, C. W.; Yun, J. Y.; Kang, J. A.; Kang, J.; Lee, S. E.; Yoon, C. H.; Boo, K.; Ham, S.; Roh, T. Y.; Jun, J. K.; Lee, H.; Baek, S. H.; Kim, H. S. (2016). "CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages". Cell Stem Cell. 18 (4): 508–521. doi:10.1016/j.stem.2016.01.013. PMID 26996598.
